Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901479439> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2901479439 endingPage "67" @default.
- W2901479439 startingPage "57" @default.
- W2901479439 abstract "Aim. To evaluate the effectiveness of different regimens of maintenance chemotherapy after the first line of treatment for patients with metastatic colorectal cancer. Materials and methods. We performed retrospective analyses of the data from 432 patients from 17 clinics in 14 regions of the Russian Federation who started systemic therapy for metastatic cancer in 2013. The main inclusion criterion was objective response or stabilization after the first 16 weeks of first-line therapy. Four groups of patients were compared, depending on the nature of maintenance therapy: those receiving fluoropyrimidines, a combination of fluoropyrimidines with bevacizumab, monotherapy of bevacizumab and monotherapy of anti-EGFR antibodies. The main criteria for assesment of the effectiveness of treatment were progression-free survival and overall survival. The statistical analysis was performed with the SPSS 20.0 sof tware package. Results. Maintenance therapy after completion of the first 16 weeks of the 1st line of chemotherapy was administered in 126 patients, most of them were treated with fluoropyrimidines (53.1 %). The median overall survival in the maintenance group was 27 versus 21 months in the observation group, p=0.01, HR=0.78 (95 % CI 0.6–1.02) Median progression-free survival in the maintenance group was 11 vs 7 months in the observation group (p<0.001, HR=0.6, 95 % CI 0.5–0.8). The worst results of progression-free survival were observed in the group with monotherapy of bevacizumab – median was 10 months versus 12 months in the fluoropyrimidine monotherapy group, 10 months for the combination of fluoropyrimidine with bevacizumab and 14 months for monotherapy of the anti-EGFR (p=0,9, HR=1.0, 95 % CI 0.9–1.2). Conclusions. There were no statistical differences in survival with different regimens of maintenance therapy. Monotherapy of bevacizumab in maintenance treatment was associated with the worst sur vival rates." @default.
- W2901479439 created "2018-11-29" @default.
- W2901479439 creator A5001446745 @default.
- W2901479439 creator A5007899564 @default.
- W2901479439 creator A5013339239 @default.
- W2901479439 creator A5013364644 @default.
- W2901479439 creator A5021102458 @default.
- W2901479439 creator A5036692508 @default.
- W2901479439 creator A5039310160 @default.
- W2901479439 creator A5039439893 @default.
- W2901479439 creator A5042375497 @default.
- W2901479439 creator A5043887737 @default.
- W2901479439 creator A5048011091 @default.
- W2901479439 creator A5050089199 @default.
- W2901479439 creator A5058708966 @default.
- W2901479439 creator A5061298229 @default.
- W2901479439 creator A5079081718 @default.
- W2901479439 creator A5079769552 @default.
- W2901479439 creator A5080967988 @default.
- W2901479439 creator A5089793618 @default.
- W2901479439 creator A5018894308 @default.
- W2901479439 date "2018-11-13" @default.
- W2901479439 modified "2023-09-27" @default.
- W2901479439 title "EFFECTIVENESS OF MAINTENANCE THERAPY AFTER THE END OF THE FIRST LINE OF TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER – THE RESULTS OF A POPULATION-BASED STUDY" @default.
- W2901479439 doi "https://doi.org/10.18027/2224-5057-2018-8-3-57-67" @default.
- W2901479439 hasPublicationYear "2018" @default.
- W2901479439 type Work @default.
- W2901479439 sameAs 2901479439 @default.
- W2901479439 citedByCount "0" @default.
- W2901479439 crossrefType "journal-article" @default.
- W2901479439 hasAuthorship W2901479439A5001446745 @default.
- W2901479439 hasAuthorship W2901479439A5007899564 @default.
- W2901479439 hasAuthorship W2901479439A5013339239 @default.
- W2901479439 hasAuthorship W2901479439A5013364644 @default.
- W2901479439 hasAuthorship W2901479439A5018894308 @default.
- W2901479439 hasAuthorship W2901479439A5021102458 @default.
- W2901479439 hasAuthorship W2901479439A5036692508 @default.
- W2901479439 hasAuthorship W2901479439A5039310160 @default.
- W2901479439 hasAuthorship W2901479439A5039439893 @default.
- W2901479439 hasAuthorship W2901479439A5042375497 @default.
- W2901479439 hasAuthorship W2901479439A5043887737 @default.
- W2901479439 hasAuthorship W2901479439A5048011091 @default.
- W2901479439 hasAuthorship W2901479439A5050089199 @default.
- W2901479439 hasAuthorship W2901479439A5058708966 @default.
- W2901479439 hasAuthorship W2901479439A5061298229 @default.
- W2901479439 hasAuthorship W2901479439A5079081718 @default.
- W2901479439 hasAuthorship W2901479439A5079769552 @default.
- W2901479439 hasAuthorship W2901479439A5080967988 @default.
- W2901479439 hasAuthorship W2901479439A5089793618 @default.
- W2901479439 hasBestOaLocation W29014794391 @default.
- W2901479439 hasConcept C121608353 @default.
- W2901479439 hasConcept C126322002 @default.
- W2901479439 hasConcept C141071460 @default.
- W2901479439 hasConcept C143998085 @default.
- W2901479439 hasConcept C2776694085 @default.
- W2901479439 hasConcept C2776999253 @default.
- W2901479439 hasConcept C2777802072 @default.
- W2901479439 hasConcept C2778283404 @default.
- W2901479439 hasConcept C2780739268 @default.
- W2901479439 hasConcept C2908647359 @default.
- W2901479439 hasConcept C526805850 @default.
- W2901479439 hasConcept C71924100 @default.
- W2901479439 hasConcept C99454951 @default.
- W2901479439 hasConceptScore W2901479439C121608353 @default.
- W2901479439 hasConceptScore W2901479439C126322002 @default.
- W2901479439 hasConceptScore W2901479439C141071460 @default.
- W2901479439 hasConceptScore W2901479439C143998085 @default.
- W2901479439 hasConceptScore W2901479439C2776694085 @default.
- W2901479439 hasConceptScore W2901479439C2776999253 @default.
- W2901479439 hasConceptScore W2901479439C2777802072 @default.
- W2901479439 hasConceptScore W2901479439C2778283404 @default.
- W2901479439 hasConceptScore W2901479439C2780739268 @default.
- W2901479439 hasConceptScore W2901479439C2908647359 @default.
- W2901479439 hasConceptScore W2901479439C526805850 @default.
- W2901479439 hasConceptScore W2901479439C71924100 @default.
- W2901479439 hasConceptScore W2901479439C99454951 @default.
- W2901479439 hasIssue "3" @default.
- W2901479439 hasLocation W29014794391 @default.
- W2901479439 hasOpenAccess W2901479439 @default.
- W2901479439 hasPrimaryLocation W29014794391 @default.
- W2901479439 hasRelatedWork W1963973664 @default.
- W2901479439 hasRelatedWork W1999852871 @default.
- W2901479439 hasRelatedWork W2066462266 @default.
- W2901479439 hasRelatedWork W2094410967 @default.
- W2901479439 hasRelatedWork W2107314204 @default.
- W2901479439 hasRelatedWork W2768563229 @default.
- W2901479439 hasRelatedWork W2943188539 @default.
- W2901479439 hasRelatedWork W3198049980 @default.
- W2901479439 hasRelatedWork W3206162654 @default.
- W2901479439 hasRelatedWork W3206914879 @default.
- W2901479439 hasVolume "8" @default.
- W2901479439 isParatext "false" @default.
- W2901479439 isRetracted "false" @default.
- W2901479439 magId "2901479439" @default.
- W2901479439 workType "article" @default.